Home > Result Summaries: Compounds > belimumab Result Summaries: belimumab GSKStudy ID Phase Title Summary (Download) 114243 phase 1 GSK1550188, A randomised, single-blind, placebo controlled, dose ascending, single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic of GSK1550188 in Japanese subjects with Systemic Lupus Erythematosus (SLE) (1 citation(s)) 114246 phase 3 Effectiveness of belimumab treatment in a subpopulation of systemic lupus erythematosus (SLE) patients: a pooled analysis of BLISS-52 and BLISS-76 (0 citation(s)) 115030 phase 3 Efficacy and Safety of Belimumab in a Subgroup of Systemic Lupus Erythematosus (SLE) Patients with Higher Disease Activity (anti-dsDNA positive and low complement): A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies (1 citation(s)) 115563 n\a PGx418 Exploratory Pharmacogenetic Research on Efficacy of BENLYSTA (belimumab) in BEL110752 (BLISS-52) and BEL110751 (BLISS-76) (0 citation(s)) 116119 phase 1 An open label, randomized, parallel, single dose study to investigate safety and pharmacokinetics following intravenous administration and subcutaneous administration of GSK1550188 in healthy Japanese males (0 citation(s)) 117295 phase 4 Evaluation of use of belimumab in clinical practice settings (0 citation(s))
